Use of Lytic Bacteriophage for Control of Experimental
            <i>Escherichia coli</i>
            Septicemia and Meningitis in Chickens and Calves

Barrow, Paul; Lovell, M. A.; Berchieri, Ângelo

doi:10.1128/cdli.5.3.294-298.1998

Cited by 257 publications

(146 citation statements)

References 29 publications

Supporting

Mentioning

129

Contrasting

Unclassified

Order By: Relevance

“…Injections are commonly used to deliver bacteriophages systemically, mostly in animal models. Phages have been injected intraperitoneally (IP), [111][112][113][114][115][116] intramuscularly (IM), [117][118][119][120][121][122] subcutaneously (SC) 113,123,124 or directly into the blood intravenously (IV), [125][126][127][128][129][130] including IV administration to humans. 131,132 All types of injections have been demonstrated as efficient means of phage delivery to virtually all organs and tissues.…”

Section: Injectionsmentioning

confidence: 99%

See 1 more Smart Citation

Phage therapy: What factors shape phage pharmacokinetics and bioavailability? Systematic and critical review

Dąbrowska

2019

Medicinal Research Reviews

230

212

View full text Add to dashboard Cite

Bacteriophages are not forgotten viruses anymore: scientists and practitioners seek to understand phage pharmacokinetics in animals and humans, investigating bacteriophages as therapeutics, nanocarriers or microbiome components. This review provides a comprehensive overview of factors that determine phage circulation, penetration, and clearance, and that in consequence determine phage applicability for medicine. It makes use of experimental data collected by the phage community so far (PubMed 1924‐2016, including non‐English reports), combining elements of critical and systematic review. This study covers phage ability to enter a system by various routes of administration, how (and if) the phage may access various tissues and organs, and finally what mechanisms determine the courses of phage clearance. The systematic review method was applied to analyze (i) phage survival in the gut (gut transit) and (ii) phage ability to enter the mammalian system by many administration routes. Aspects that have not yet been covered by a sufficient number of reports for mathematical analysis, as well as mechanisms underlying trends, are discussed in the form of a critical review. In spite of the extraordinary diversity of bacteriophages and possible phage applications, the analysis revealed that phage morphology, phage specificity, phage dose, presence of sensitive bacteria or the characteristics of treated individuals (age, taxonomy) may affect phage bioavailability in animals and humans. However, once phages successfully enter the body, they reach most organs, including the central nervous system. Bacteriophages are cleared mainly by the immune system: innate immunity removes phages even when no specific response to bacteriophages has yet developed.

show abstract

Section: Injectionsmentioning

confidence: 99%

“…Systemically administered phages have been observed in feces of calves and mice, 117,120 in intestines of mice, rabbits and chickens 80,149,150,161 and in murine stomach. 89,139 Stomach penetration from blood was studied in a model where mice were or were not prevented to swallow.…”

Section: Phages In Organsmentioning

confidence: 99%

Phage therapy: What factors shape phage pharmacokinetics and bioavailability? Systematic and critical review

Dąbrowska

2019

Medicinal Research Reviews

230

212

View full text Add to dashboard Cite

show abstract

“…The control group consisted of animals not receiving bacteriophages. The mortality rate in the study group was 0% as compared to 100% mortality in the control group (Barrow et al 1998). Biswas et al (2002) carried out a study of bacteriophage therapy in BALB/c mice infected with a vancomycin-resistant Enterococcus sp., strain.…”

Section: A Sepsis Modelmentioning

confidence: 99%

Therapeutic bacteriophages as a rescue treatment for drug‐resistant infections – anin vivostudies overview

Kwiatek

Parasion²,

Nakonieczna

2019

J Appl Microbiol

View full text Add to dashboard Cite

Summary Bacteriophages, highly prevalent in all environments, have found their use in medicine as an alternative or complement to antibiotics. The therapeutic use of bacteriophages was particularly popular in the 1920s and 1930s, until the discovery and introduction of antibiotics. Due to the dynamic growth of antibiotic resistance among bacterial strains, numerous international institutions (such as the FDA) have declared the search for novel treatment modalities to be of the highest priority. To date, bacteriophage therapy has not been registered for general use in Western countries. The regulation of biological medicinal products (within medicinal product regulation) does not contain a specific documentation frame for bacteriophages (only for vaccines, blood derived products, etc.) which, as active substances, need to meet specific requirements. Recently, the FDA allowed bacteriophage therapy to be used in the United States, via the Emergency Investigational New Drug scheme; clinical trials to compare the safety and efficacy of bacteriophage therapy are also permitted. To date, several therapeutic products of this type have made it to phase I or II; some clinical programmes have also been completed. This article cites numerous animal model studies and registered clinical trials, showing the safety and effectiveness of bacteriophage therapy, including infections caused by bacterial strains resistant to antibiotic treatment.

show abstract

“…Recently, well-controlled animal models have demonstrated that phages can rescue animals (chickens, mice, calves, pigs, lambs, fishes, etc.) from a variety of harmful infections, like E. coli or Salmonella infections Huggins 1982, 1983;Smith et al 1987;Berchieri et al 1991;Barrow et al 1998;Park et al 2000;Sklar and Joerger 2001;Huff et al 2002;Bru Ronda et al 2003;Huff et al 2003).…”

Section: Introductionmentioning

confidence: 99%

Isolation and characterization of bacteriophages for avian pathogenicE. colistrains

Oliveira

Sillankorva

Quinta³

et al. 2009

Journal of Applied Microbiology

View full text Add to dashboard Cite

Aims: To isolate and characterize bacteriophages, and to evaluate its lytic performance against avian pathogenic Escherichia coli (APEC) strains with high patterns of antibiotic resistance, in order to select phages for a therapeutic product to treat colibacillosis in chickens. Methods and Results: Bacteriophages were isolated from poultry sewage and tested against 148 O‐serotyped APEC strains. The morphological characterization of the bacteriophages was made by transmission electronic microscopy (TEM) observations and the genetic comparison between bacteriophages DNA was performed by restriction fragment length polymorphism (RFLP) patterns. Results showed that 70·5% of the tested E. coli strains were sensitive to a combination of three of the five isolated phages, that seemed to be virulent and taxonomically belong to the Caudovirales order. Two of them look like 16–19, T4‐like phages (Myoviridae) and the third is a T1‐like phage and belongs to Syphoviridae family. All of them are genetically different. Conclusions: It was possible to obtain a combination of three different lytic bacteriophages with broad lytic spectra against the most prevalent O‐serotypes of APEC. Significance and Impact of the Study: Data reported in this study, presents an in vitro well studied phage product to be used as antimicrobial agent to treat colibacillosis in poultry industry.

show abstract

Use of Lytic Bacteriophage for Control of Experimental Escherichia coli Septicemia and Meningitis in Chickens and Calves

Cited by 257 publications

References 29 publications

Phage therapy: What factors shape phage pharmacokinetics and bioavailability? Systematic and critical review

Phage therapy: What factors shape phage pharmacokinetics and bioavailability? Systematic and critical review

Therapeutic bacteriophages as a rescue treatment for drug‐resistant infections – anin vivostudies overview

Isolation and characterization of bacteriophages for avian pathogenicE. colistrains

Contact Info

Product

Resources

About